Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk A/S : Share repurchase programme (Form 6-K)

06/22/2021 | 09:23am EDT

Novo Nordisk A/S - Share repurchase programme

Bagsværd, Denmark, 21 June 2021 - On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the 'Safe Harbour Rules'). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021.

Under the programme initiated 7 May 2021, Novo Nordisk will repurchase B shares for an amount up to DKK 3.3 billion in the period from 10 May 2021 to 3 August 2021.

Since the announcement as of 14 June 2021, the following transactions have been made:

Number of

B shares

Average

purchase price

Transaction

value, DKK

Accumulated, last announcement 2,501,917 1,221,586,321
14 June 2021 105,000 515.26 54,102,817
15 June 2021 100,000 518.89 51,888,651
16 June 2021 100,000 519.88 51,987,857
17 June 2021 100,000 510.60 51,059,795
18 June 2021 100,000 515.82 51,581,703
Accumulated under the programme 3,006,917 1,482,207,144

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

Page 2 of 2

With the transactions stated above, Novo Nordisk owns a total of 14,210,192 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 2,310,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 18 billion during a 12- month period beginning 3 February 2021. As of 18 June 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 15,371,694 B shares at an average share price of DKK 459.84 per B share equal to a transaction value of DKK 7,068,566,393.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

Further information

Media:
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Michael Bachner (US) +1 609 664 7308 mzyb@novonordisk.com
Investors:
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com
Ann Søndermølle Rendbæk +45 3075 2253 arnd@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:
www.novonordisk.com
CVR no:

24 25 67 90

Company announcement No 41 / 2021

Disclaimer

Novo Nordisk A/S published this content on 22 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2021 13:22:06 UTC.


© Publicnow 2021
All news about NOVO NORDISK A/S
07/19NOVO NORDISK A/S : – Share repurchase programme
AQ
07/19NOVO NORDISK : Barclays maintains a Buy rating
MD
07/13PROTHENA : Oppenheimer Adjusts Prothena PT to $76 From $54, Maintains Outperform..
MT
07/12NOVO NORDISK A/S : to buy Prothena's heart drug in deal worth up to $1.2 billion
RE
07/12PROTHENA : Sells ATTR Amyloidosis Program to Novo Nordisk
MT
07/12NOVO NORDISK A/S : To Acquire Rights To Prothena's ATTR Amyloidosis Program
MT
07/12NOVO NORDISK : Jefferies gives a Sell rating
MD
07/09President Biden's Competition Order to Crack Down on Antitrust Practices by B..
MT
07/07NOVO NORDISK A/S : Parent Acquires Minority Stake in Availity
MT
07/07SYNACT PHARMA : Appoints New Chief Medical Officer
MT
More news
Financials
Sales 2021 133 B 21 099 M 21 099 M
Net income 2021 44 318 M 7 017 M 7 017 M
Net cash 2021 6 391 M 1 012 M 1 012 M
P/E ratio 2021 29,7x
Yield 2021 1,70%
Capitalization 1 309 B 207 B 207 B
EV / Sales 2021 9,78x
EV / Sales 2022 8,97x
Nbr of Employees 45 157
Free-Float 69,8%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Last Close Price 570,90 DKK
Average target price 485,37 DKK
Spread / Average Target -15,0%
EPS Revisions
Managers and Directors
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S33.81%188 446
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
NOVARTIS AG1.10%207 246